Bleeding characteristics of patients with congenital hemophilia and inhibitors: Data from a postmarketing study of recombinant activated factor VII (SMART-7)

被引：0
|
作者：
Demartis, Francesco [1 ]
Benson, Gary [2 ]
Batorova, Angelika [3 ]
Cepo, Katarina [4 ]
Zak, Marek [4 ]
Chambost, Herve [5 ]
机构：
[1] Azienda Osped Univ Careggi, Haemophilia Ctr, Florence, Italy
[2] Belfast City Hosp, Northern Ireland Haemophilia Ctr, Belfast, Antrim, North Ireland
[3] Comenius Univ, Fac Med, Univ Hosp, Bratislava, Slovakia
[4] Novo Nordisk AS, Soborg, Denmark
[5] Hop Enfants La Timone, Marseille Univ Hosp, Pediat Hematol Unit, Marseille, France
来源：
HAEMOPHILIA | 2016年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：68 / 68
页数：1
相关论文
共 50 条
  • [41] Safety and efficacy of recombinant activated coagulation factor VII in congenital hemophilia with inhibitors in the home treatment setting: A review of clinical studies and registries
    Young, Guy
    Escobar, Miguel A.
    Pipe, Steven W.
    Cooper, David L.
    AMERICAN JOURNAL OF HEMATOLOGY, 2017, 92 (09) : 940 - 945
  • [42] Recombinant Activated Factor VII in Controlling Bleeding in Non-Hemophiliac Patients
    Faydhi, Ali A.
    Al-Shabassy, Adel M.
    Kassem, Yasser A.
    Al Ama, Mohammed Nabil
    Faydhi, Abdullah A.
    AlShareef, Ali
    BAHRAIN MEDICAL BULLETIN, 2012, 34 (03) : 117 - +
  • [43] Safety of recombinant activated coagulation factor VII in non-hemophilia patients.
    Skolnick, BE
    Rojkjaer, LP
    Seremetis, SV
    BLOOD, 2004, 104 (11) : 80B - 80B
  • [44] A new approach to treatment of bleeding episodes in young hemophilia patients:: a single bolus megadose of recombinant activated factor VII (NovoSeven®)
    Kenet, G
    Lubetsky, A
    Luboshitz, J
    Martinowitz, U
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2003, 1 (03) : 450 - 455
  • [45] Use of recombinant activated factor VII for acute bleeding episodes in acquired hemophilia: final analysis from the Hemostasis and Thrombosis Research Society Registry acquired hemophilia study
    Ma, Alice D.
    Kessler, Craig M.
    Al-Mondhiry, Hamid A. B.
    Gut, Robert Z.
    Cooper, David L.
    BLOOD COAGULATION & FIBRINOLYSIS, 2016, 27 (07) : 753 - 760
  • [46] Recombinant Factor VIIa (Eptacog Alfa)A Review of its Use in Congenital Hemophilia with Inhibitors, Acquired Hemophilia, and Other Congenital Bleeding Disorders
    Katherine F. Croom
    Paul L. McCormack
    BioDrugs, 2008, 22 : 121 - 136
  • [47] Recombinant factor VIIa (Eptacog Alfa) - A review of its use in congenital hemophilia with inhibitors, acquired hemophilia, and other congenital bleeding disorders
    Croom, Katherine F.
    McCormack, Paul L.
    BIODRUGS, 2008, 22 (02) : 121 - 136
  • [48] The comparison of efficacy between recombinant activated factor VII (ARYOSEVEN®) and NOVOSEVEN® in patients with congenital factor VII deficiency
    Faranoush, M.
    Hassan, A.
    Toogeh, G.
    Karimi, M.
    Eshghi, P.
    Managchi, M. R.
    Hamid, H.
    Kamyar, K.
    Heshmat, R.
    Keykhahi, B.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 1198 - 1199
  • [49] Analyses of recombinant activated factor VII treatments from clinical practice for rapid bleeding and acute pain control in haemophilia patients with inhibitors
    Salaj, P.
    Ovesna, P.
    Penka, M.
    Hedner, U.
    HAEMOPHILIA, 2012, 18 (06) : e409 - e411
  • [50] Recombinant factor VIIa (rFVIIa) treatment of bleeding in congenital factor VII deficiency (C7D): analysis from the hemophilia and thrombosis research society (HTRS) registry
    Saxena, K.
    Neufeld, E. J.
    Kraut, E. H.
    Cooper, D. L.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 473 - 473
12345